Your browser doesn't support javascript.
loading
Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
van Schaik, Mieke; Arends, Eline J; Soonawala, Darius; van Ommen, Ellen; de Leeuw, Karina; Limper, Maarten; van Paassen, Pieter; Huizinga, Tom W J; Toes, René E M; van Kooten, Cees; Rotmans, Joris I; Rabelink, Ton J; Teng, Y K Onno.
Afiliação
  • van Schaik M; Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Internal Medicine - Section Nephrology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.
  • Arends EJ; Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Internal Medicine - Section Nephrology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.
  • Soonawala D; Department of Nephrology, HagaZiekenhuis, Els Borst-Eilersplein 275, 2545 AA, The Hague, the Netherlands.
  • van Ommen E; Department of Nephrology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands.
  • de Leeuw K; Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
  • Limper M; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands.
  • van Paassen P; Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands.
  • Huizinga TWJ; Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.
  • Toes REM; Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.
  • van Kooten C; Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Internal Medicine - Section Nephrology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.
  • Rotmans JI; Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Internal Medicine - Section Nephrology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.
  • Rabelink TJ; Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Internal Medicine - Section Nephrology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.
  • Teng YKO; Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Internal Medicine - Section Nephrology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands. Y.K.O.Teng@lumc.nl.
Trials ; 23(1): 939, 2022 Nov 12.
Article em En | MEDLINE | ID: mdl-36371234
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Nefrite Lúpica / Lúpus Eritematoso Sistêmico Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Nefrite Lúpica / Lúpus Eritematoso Sistêmico Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article